Target Name: GPR183
NCBI ID: G1880
Review Report on GPR183 Target / Biomarker Content of Review Report on GPR183 Target / Biomarker
GPR183
Other Name(s): Lymphocyte-specific G protein-coupled receptor | Epstein-Barr virus induced gene 2 (lymphocyte-specific G protein-coupled receptor) | Epstein-Barr virus-induced G-protein coupled receptor 2 | G-protein coupled receptor 183 | GP183_HUMAN | EBI2 | EBV-induced G-protein coupled receptor 2 | epstein-Barr virus-induced G-protein coupled receptor 2 | EBV-induced G protein-coupled receptor 2 | G protein-coupled receptor 183 | hEBI2

GPR183: A Potential Drug Target and Biomarker

G-protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. GPR183, a GPCR located on the surface of cancer cells, is a potential drug target and biomarker for various diseases, including cancer.

GPR183 is a 19-kDa protein that is expressed in various tissues, including the brain, heart, kidneys, and pancreas. It is a GPCR that is known to play a role in the regulation of pain perception and neurotransmission. GPR183 is a potential drug target because of its involvement in pain signaling and its potential role in the development of chronic pain.

GPR183 is also a potential biomarker for various diseases, including cancer. The expression of GPR183 has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that GPR183 may be a useful biomarker for cancer diagnosis and treatment.

One of the challenges in the development of new cancer treatments is the lack of specific targets for cancer therapy. The GPCRs, including GPR183, provide a promising avenue for the development of new cancer treatments. By targeting GPR183, researchers can develop new drugs that specifically target this protein and disrupt its function in cancer cells.

In addition to its potential as a drug target, GPR183 is also a potential biomarker for cancer. The expression of GPR183 has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that GPR183 may be a useful biomarker for cancer diagnosis and treatment.

GPR183 is a GPCR that is involved in the regulation of pain perception and neurotransmission. Its expression is known to be elevated in various tissues, including the brain, heart, kidneys, and pancreas. This suggests that GPR183 may be a potential drug target for cancer therapy.

In conclusion, GPR183 is a potential drug target and biomarker for various diseases, including cancer. Its involvement in pain signaling and its potential role in the development of chronic pain make it an attractive target for cancer treatment. Further research is needed to fully understand the function of GPR183 and its potential as a drug and biomarker.

Protein Name: G Protein-coupled Receptor 183

Functions: G-protein coupled receptor expressed in lymphocytes that acts as a chemotactic receptor for B-cells, T-cells, splenic dendritic cells, monocytes/macrophages and astrocytes (By similarity). Receptor for oxysterol 7-alpha,25-dihydroxycholesterol (7-alpha,25-OHC) and other related oxysterols (PubMed:21796212, PubMed:22875855, PubMed:22930711). Mediates cell positioning and movement of a number of cells by binding the 7-alpha,25-OHC ligand that forms a chemotactic gradient (By similarity). Binding of 7-alpha,25-OHC mediates the correct localization of B-cells during humoral immune responses (By similarity). Guides B-cell movement along the B-cell zone-T-cell zone boundary and later to interfollicular and outer follicular regions (By similarity). Its specific expression during B-cell maturation helps position B-cells appropriately for mounting T-dependent antibody responses (By similarity). Collaborates with CXCR5 to mediate B-cell migration; probably by forming a heterodimer with CXCR5 that affects the interaction between of CXCL13 and CXCR5 (PubMed:22913878). Also acts as a chemotactic receptor for some T-cells upon binding to 7-alpha,25-OHC ligand (By similarity). Promotes follicular helper T (Tfh) cells differentiation by positioning activated T-cells at the follicle-T-zone interface, promoting contact of newly activated CD4 T-cells with activated dendritic cells and exposing them to Tfh-cell-promoting inducible costimulator (ICOS) ligand (By similarity). Expression in splenic dendritic cells is required for their homeostasis, localization and ability to induce B- and T-cell responses: GPR183 acts as a chemotactic receptor in dendritic cells that mediates the accumulation of CD4(+) dendritic cells in bridging channels (By similarity). Regulates migration of astrocytes and is involved in communication between astrocytes and macrophages (PubMed:25297897). Promotes osteoclast precursor migration to bone surfaces (By similarity). Signals constitutively through G(i)-alpha, but not G(s)-alpha or G(q)-alpha (PubMed:21673108, PubMed:25297897). Signals constitutively also via MAPK1/3 (ERK1/2) (By similarity)

The "GPR183 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR183 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8 | GRAMD1A | GRAMD1B | GRAMD1C | GRAMD2A | GRAMD2B | GRAMD4 | GRAMD4P2 | GRAMD4P5 | GRAMD4P7 | Granzyme | GRAP | GRAP2 | GRAPL | GRAPL-AS1 | GRASLND | GRB10 | GRB14 | GRB2 | GRB7 | GREB1 | GREB1L | GREM1 | GREM1-AS1 | GREM2 | GREP1 | GRHL1 | GRHL2